Equities

Wuhan Keqian Biology Co Ltd

688526:SHH

Wuhan Keqian Biology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)11.31
  • Today's Change-0.17 / -1.48%
  • Shares traded853.20k
  • 1 Year change-42.91%
  • Beta1.8738
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,0081,9361,311
Total Receivables, Net381441326
Total Inventory145169109
Prepaid expenses7.699.1210
Other current assets, total255.374.90
Total current assets2,5662,5611,761
Property, plant & equipment, net859905904
Goodwill, net3.313.31--
Intangibles, net606057
Long term investments1,1690.200.15
Note receivable - long term------
Other long term assets--822961
Total assets4,6714,3913,725
LIABILITIES
Accounts payable132196196
Accrued expenses899356
Notes payable/short-term debt24119446
Current portion long-term debt/capital leases810.6560
Other current liabilities, total215140134
Total current liabilities758624492
Total long term debt5.751470
Total debt327342106
Deferred income tax135730
Minority interest2.032.070.44
Other liabilities, total576449
Total liabilities836894572
SHAREHOLDERS EQUITY
Common stock466466465
Additional paid-in capital1,1411,1351,115
Retained earnings (accumulated deficit)2,2041,8971,576
Treasury stock - common(0.57)(1.12)(1.86)
Unrealized gain (loss)26----
Other equity, total(0.96)----
Total equity3,8363,4973,153
Total liabilities & shareholders' equity4,6714,3913,725
Total common shares outstanding466466465
Treasury shares - common primary issue0.040.080.13
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.